UAE – Pharmaceutical giant GSK plc, formerly GlaxoSmithKline plc., with support from Dubai-based pulmonologists and global experts has unveiled its advanced training programme on the management of respiratory diseases dubbed RespiVerse in Dubai.
RespiVerse will be rolled out globally in the form of regional masterclasses with an aim to upskill a large number of healthcare professionals across the United Arab Emirates (UAE) and the wider Middle East and Africa region (MENA).
Through the GSK-led training programme, doctors will be trained to become trainers in their respective market, with the aim of ultimately reaching and upskilling over 40,000 doctors by 2023.
In a press release, GSK said: “RespiVerse provides a communication channel for pulmonary experts across Emerging Markets to share their clinical insights on the relevant issues impacting the treatment decisions, diagnosis, and management of respiratory diseases.”
The new program provides a platform for experts to make exchanges on upcoming pharmacological modalities and approaches that are transforming the way pulmonologists address the gaps in the management of respiratory diseases for better health outcomes for patients.
“As a leader in the respiratory therapeutic field, GSK reaffirms its commitment through the RespiVerse programme to improve the quality of life of millions of patients with respiratory conditions,” the UK-based company informed.
Through RespiVerse, GSK aims to strengthen the partnership and collaboration with pulmonologists and other respiratory experts from across 12 countries in Emerging Markets, including the UAE, and uplift the standard of care of patients suffering from chronic respiratory diseases.
The training programme also seeks to curb the growing burden of chronic pulmonary diseases, such as Asthma, Severe Asthma, and Chronic Obstructive Pulmonary Disease (COPD), which pose a major health threat to people in the Middle East.
Moreover, the global science-led healthcare company GlaxoSmithKline unveiled the innovative health initiative during an expert forum on the management of respiratory diseases in Dubai.
GSK stated: “The forum is the first in a global series of expert forums to explore the current diagnosis and management landscape of chronic pulmonary diseases.”
The expert forum featured in-depth discussions about relevant topics concerning the standards of care of respiratory patients, recent trends in treatment protocols, and pharmacological approaches.
In addition, they explored precision medicine and proactive regular dosing (PRD), which are changing the mindsets of many pulmonary experts with regards to making treatment decisions and managing chronic respiratory diseases.
Gizem Akalin, Vice President and General Manager for GSK Gulf, outlined that disease management of respiratory diseases illnesses in the UAE is one of the top priorities at the research-based pharmaceutical and healthcare company.
He further pointed out that management of chronic diseases is part of the UAE Government’s vision to improve healthcare in the country within all fields and for all diseases.
“We are as ever committed to growing our presence in the region, particularly the UAE, contributing to improving the quality of healthcare, and promoting a better and healthier life for its residents,” Akalin added.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.